SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights

First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2

EQ

Related stories